Cholecystokinin (CCK) was first isolated from the gastrointestinal tract as an intestinal 33-amino acid peptide hormone that stimulates the secretion of pancreatic amylase and other enzymes. CCK was subsequently also identified in the central nervous system (CNS), where it probably acts as a neurotransmitter or neuromodulator. CCK receptors have been divided into CCK-A (alimentary) and CCK-B (brain) which mediate the diverse biological functions of CCK. CCK-A receptors are primarily located in the gut where they mediate pancreatic enzyme secretion, gallbladder contraction, gastric emptying, and intestinal motility, 1) but they are also found in discrete regions of brain 2) where they are believed to play a significant role in neuropsychiatric disorders.
3) CCK-B receptors are widely distributed in the CNS and studies in animals and humans using CCK-B receptor antagonists have suggested that anxiety, panic attacks, analgesia, and satiety may be modulated through CCK-B receptors. 4) Gastrin is the first gastrointestinal hormone 5) to be identified and it plays a key role in the regulation of gastric acid secretion. The binding characteristics of high affinity ligands for brain CCK-B and stomach gastrin receptors have been demonstrated to be very similar. 6) Therefore, gastrin and CCK-B receptors are described as gastrin/CCK-B receptors, and studies in various animal models have suggested the potential usefulness of these receptor antagonists for treating ulcerogenic diseases, CNS disorders, and certain tumors. 7) It has been reported that the long-term treatment of gastric ulcers with histamine H 2 -receptor antagonists or proton pump inhibitors causes hypergastrinemia and hyperplasia of the oxyntic mucosa, resulting in the gastric acid rebound phenomenon. 8) It is hoped that gastrin receptor antagonists will have a reduced propensity to produce these side-effects because of their completely different mode of action. Hence, they are expected to have clear clinical advantages over currently used drugs.
In recent years, a sustained research effort has been made to discover potent and selective antagonists of gastrin/CCK-B receptors. The benzodiazepine series of antagonists, exemplified by L-365,260 (1), has been particularly well documented. 9) Various modifications of the structure of L-365,260 have been carried out, and it has been reported that replacing the N1-methyl group of L-365,260 with an alkyl chain, such as isobutyl, cyclopropylmethyl and n-propyl, generally leads to improved affinity for CCK-B receptors. 10) Another type of analogue at the N1-position of L-365,260 is replaced by a novel series of N1-aroylmethyl compounds. YM022 (2) is the leading compound of this series and one of the most potent gastrin/CCK-B receptor antagonists. 11) YM022 also suppresses gastric acid secretion in pylorus-ligated rats in a dose-dependent manner when administered orally, and its potency in this animal model is comparable with that of famotidine, an H 2 -receptor antagonist. 12) In a previous paper, we reported a series of phenoxyacetic acid derivatives which have potent gastrin receptor antagonistic activity. 13) In particular, DA-3934 (5), possessing an acid function in the ureido-phenyl ring, showed high affinity for human gastrin receptors, similar to that of YM022, and good selectivity for gastrin/CCK-B receptors over CCK-A receptors.
13b) However, the anti-gastric acid secretory activity of DA-3934 in rats was weaker than that of YM022.
With the objective of discovering new antagonists which retain the receptor binding affinity of DA-3934 and also inhibit acid secretion more potently than DA-3934, we reconsidered our molecular modeling studies which had shown that the N-methyl-N-phenylcarbamoylmethyl moiety of DA-3934 probably corresponds to the N1-aroylmethyl moiety of YM022. 13a) As described above, improvements in potency as gastrin/CCK-B receptor antagonists could be achieved by introducing a hydrophobic group at the N1-position of the benzodiazepine gastrin receptor antagonists. Hence, we tried to increase the receptor antagonist potency of phenoxyacetic DA-3797 (4), which differ principally in the substitution pattern of the phenyl ring, showed similar profiles of biological activity.
13a) Therefore, we tried to synthesize new meta-substituted phenoxyacetic acid derivatives 39a-c which were analogues of DZ-3514 (Chart 4). Synthesis of 39a-c was carried out by using the same route as described for the preparation of 22a-m, but starting from the appropriate meta-substituted precursor. Thus, the intermediate 33 was prepared from m-nitrophenol 32 by condensation with bromide 9.
Pharmacological Evaluation and Discussion
Receptor binding assays of the newly synthesized compounds were used to investigate their affinities for gastrin and CCK-A receptors. 17) The results are summarized in Tables  1-3 . For the primary in vivo study of compounds which showed high affinity for human gastrin receptors, the inhibition of pentagastrin-induced gastric acid secretion in anesthetized rats was measured. Test compounds were adminis-tered intraduodenally at 1 mg/kg, and the results are shown in Tables 1 and 2 . ED 50 values were also determined for compounds which significantly inhibited gastric acid secretion at a dose of 1 mg/kg (Table 4) .
The biological activities of the compounds containing various rings in the N-alkyl substituents are shown in Table 1 . Introduction of a phenyl or cyclic alkyl group into the Nalkyl substituent was found to increase the affinity for gastrin receptors. The benzyl-type compound (22a) showed greater affinity for both gastrin and CCK-A receptors than DA-3934 (5). In the phenethyl derivative 22b, the distance between the ring and the N-atom is increased, which apparently reduces the affinity for human gastrin receptors, because the IC 50 value was some 2-fold less than that of compound 5. Replacement of the phenyl ring with a cyclohexyl ring (22c) increased the binding affinity for both human gastrin and CCK-A receptors, with IC 50 values of 0.06 and 61 nM, respectively. The activity was found to depend on the length of the alkyl chain between the ring and the N-atom, and the order of potency was methylene (22c)Ͼpropylene (22e)мethylene (22d). These results suggest that a methylene is the optimal size for affinity for human gastrin receptors. It is assumed that these alkyl moieties interact with the receptor by occupying a lipophilic pocket of finite size.
The optimal distance between the ring and the N-atom having been fixed, the effects of changing the ring size were explored. The IC 50 value of compound 31a, which has a cyclopropyl ring, was similar to that of compound 5. Com- pounds with larger rings, cyclobutyl (31b), cyclopentyl (31c), and cycloheptyl (31d), exhibited significantly greater affinity for human gastrin receptors than compound 31a, and their IC 50 values were very similar to that of compound 22c, which has a cyclohexyl ring ( Table 1 ). The potency of compound 31e, possessing a much bulkier adamantyl group, was significantly reduced. Therefore, it appears that the ring size for high affinity for human gastrin receptors should be in the range cyclobutyl to cycloheptyl. A comparison of compounds having straight and branched chains is shown in Table 2 . Compounds having a chain length in the range of three to six carbon atoms were synthesized. As noted above, it is proposed that the lipophilic pocket for the alkyl chain is of limited size. Hence, it was expected that compounds possessing either truncated or elongated side-chains would show reduced affinity for gastrin receptors.
Among the compounds substituted with alkyl groups having a chain length of three carbon atoms, introduction of the 2-methylpropyl (22g) and 2,2-dimethylpropyl (31g) groups resulted in compounds with activities which were higher than that of compound 5. Compound 22g showed 3-fold greater affinity for both human gastrin and CCK-A receptors than compound 31g. This difference in potency may be due to a (14) , n-butyl (22f), 2-ethylbutyl (31f), and 3,3-dimethylbutyl (31h) groups, there was little difference in affinity for gastrin receptors. The IC 50 values ranged from 0.10 to 0.13 nM, and therefore, it was concluded that the affinity for human gastrin receptors is little affected by alkyl chain branching.
In general, compounds substituted with five carbon atom alkyl chains exhibited high affinity for human gastrin receptors ( Table 2 ). The IC 50 values of compounds possessing 3-methylpentyl (22h), 3-ethylpentyl (22i), 4-methyl-3-pentenyl (22j), and 4-methylpentyl (22m) groups were 0.06, 0.18, 0.07, and 0.05 nM, respectively. Comparing 22j and 22m indicates that introduction of a double bond into the side-chain does not improve the affinity for human gastrin receptors. It can also be deduced that the affinity for human gastrin receptors is largely independent of branch position by comparing compounds 22h and 22m. The activity of compound 22i was somewhat reduced compared with the other three compounds; it also has a more sterically demanding alkyl group.
The activities of the compounds having six carbon atom side-chains (22k, 22l) were reduced compared with compounds substituted with a five carbon atom alkyl chain ( Table  2) . It was, therefore, concluded that the optimal length of the alkyl chain is five atoms.
In Table 3 , the receptor binding affinities of the m-phenoxyacetic acid derivatives (39a-c) are reported. These compounds showed 3-to 80-fold less potent activity compared with the corresponding o-phenoxyacetic acid derivatives, in contrast to DZ-3514 (3) and DA-3797 (4), which showed similar binding affinities for both gastrin and CCK-A receptors.
13a) It seems likely that the conformation required for high affinity for human gastrin receptors is changed by replacing the N-methyl-N-phenylcarbamoylmethyl group with an alkyl group in the m-phenoxyacetic acid series.
With regard to CCK-A receptors, compounds 22c and 22e exhibited significantly greater affinity for these receptors than most of the other compounds shown in Table 1 . Compound 22e showed relatively weak affinity for gastrin receptors, similar to that of compound 5, and thus the selectivity of 22e for gastrin receptors over CCK-A receptors was reduced. In a previous paper, 13b ) we reported that high selectivity for gastrin receptors over CCK-A receptors could be achieved by introducing oxygenated substituents into the ureido-phenyl ring. However, it was found that compounds with hydrophobic side-chains replacing the N-methyl-N-phenylcarbamoylmethyl group showed somewhat greater affinity for CCK-A receptors. Therefore, it is apparent that selectivity is affected not only by introducing oxygenated function into the ureido-phenyl ring but also by modifying the hydrophobic Nalkyl substituents. The relationship between ring size and affinity for CCK-A receptors was similar to that for gastrin receptors; compounds possessing either a small ring, like cyclopropyl (31a), or a sterically bulky ring, like adamantyl (31e), exhibited reduced affinity (Table 1) .
Among the compounds having straight and branched chains, compound 31f (2-ethylbutyl) showed relatively greater affinity for CCK-A receptors than the other compounds in Table 2 . It is noteworthy that compound 31f exhibited similar binding affinity to compound 22c (cyclohexylmethyl) at both receptors. It is possible that these two compounds adopt similar conformations at the receptor and, therefore, exhibit similar potency. On the other hand, compound 22f, with a straight chain n-butyl group, exhibited significantly weaker affinity for CCK-A receptors.
The acid secretion-inhibiting activity of compounds 22c, 31b and 31c, which exhibited high affinity for gastrin receptors among the compounds containing various rings in the Nalkyl substituents, was evaluated in vivo at a dose of 1 mg/kg. Contrary to our expectations, compound 31b did not inhibit gastric acid secretion when administered intraduodenally but rather stimulated it. Although it was not clear whether the stimulating activity of compound 31b might be due to its agonist activity or to other factors, we concluded that compound 31b would not serve our purpose. On the other hand, compounds 22c and 31c potently inhibited acid secretion and both were superior to DA-3934 (5) while compound 22c exhibited more potent activity than 31c in vivo. Among the compounds in this new series of phenoxyacetic acid derivatives, compound 22c is a promising candidate for further development, although lower gastrin/CCK-A selectivity was observed than for compound 5.
The anti-secretory activity of the five compounds which showed highest affinity for human gastrin receptors among the compounds having straight and branched chains, i.e., compounds 14, 22h, 22j, 22m, and 31f, was evaluated. It was found that compounds 31f (2-ethylbutyl) and 22h (3-methylpentyl) inhibited acid secretion more potently than compound 5 ( Table 2 ). The acid secretion-inhibiting activity of the other three compounds was similar to, or less than, that of compound 5. The affinity for human gastrin receptors and the acid secretion-inhibiting activity of 31f and 22h are similar, but compound 22h shows higher selectivity for human gastrin receptors over CCK-A receptors than compound 31f. Therefore, compound 22h is the most promising candidate for further development in this series.
The ED 50 values for the in vivo gastric acid secretion in- Table 4 . Compound 22c inhibited gastric acid secretion induced by infusion of 16 mg/kg/h pentagastrin in a dose-dependent manner when administered either intraduodenally or intravenously; the ED 50 values were 0.12 mg/kg (i.d.) and 6.0 mg/kg (i.v.), respectively. It is noted that the in vivo activity of compound 22c was also significantly greater than that of parent compound 5. Compound 22c exhibited ca. 5-fold less potency than YM022 when administered intravenously but ca. 15-fold greater potency when administered intraduodenally. Compound 22c may have shown reduced activity compared with YM022 when administered intravenously because of differences in the rates of metabolism and/or excretion.
Compound 22h also inhibited pentagastrin-induced gastric acid secretion more potently than compound 5, but was ca. 5-fold less potent than compound 22c, despite showing similar activity in vitro, probably due to a difference in absorption rate. Compound 22h is a racemic compound and, therefore, it will be necessary to synthesize both enantiomers in order to clarify their relative contributions to the pharmacological activity.
Compounds 22c and 22h may show greater in vivo activity than parent compound 5 because of their increased affinity for human gastrin receptors. Furthermore, replacement of the N-methyl-N-phenylcarbamoylmethyl group by an alkyl group reduces the hydrophobicity of the amide moiety, which may also improve absorption. Further work to modify the synthetic route so that both enantiomers of compound 22h can be prepared and to investigate the pharmacokinetics of compound 22c is in progress.
Conclusions
We have prepared a new series of phenoxyacetic acid derivatives which show enhanced in vivo acid secretion inhibiting activity compared to parent compound DA-3934 (5). Replacing the N-methyl-N-phenylcarbamoylmethyl group of compound 5 with various alkyl groups led to the discovery of compounds with increased affinity for human gastrin receptors and, with a few notable exceptions, also for CCK-A receptors. Compounds 22c and 22h exhibited potent activities in vitro and also inhibited pentagastrin-induced gastric acid secretion in rats. The anti-secretory activity of both compounds was greater than that of parent compound 5 and compared favorably with that of YM022.
Experimental
All chemicals and solvents used for synthesis were reagent-grade products and were used without additional purification. The following solvent and reagent names are abbreviated as follows: ethyl acetate (AcOEt), 4-dimethylaminopyridine (DMAP), N,N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC · HCl), trifluroacetic acid (TFA). Melting points were measured on a Yanaco micro melting point apparatus and are uncorrected. NMR spectra were obtained on a JEOL EX-400 spectrometer, with tetramethylsilane as an internal standard. Chemical shifts are reported in parts per million (ppm, d units). Splitting patterns are designated as s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad. Infrared (IR) spectra were obtained on a Hitachi 270-30 spectrometer using KBr disks. Elemental analyses were performed using a Perkin-Elmer Model 240C elemental analyzer. Merck Kieselgel 60 (70-230 mesh) was used for column chromatography.
N-(2-Benzyloxyphenyl)-N-(3-methyl-2-butenyl)-2-(N-tert-butoxycarbonylamino)acetamide (7) To a solution of 6 (17.8 g, 50 mmol) in THF (100 ml) was added NaH (60% in oil, 2.4 g, 60 mmol), and the mixture was stirred at 55°C for 1.5 h. After adding a solution of 3-methyl-2-butenyl bromide (8.9 g, 60 mmol) in THF (20 ml) to the reaction mixture with ice cooling, the resulting mixture was stirred overnight at room temperature. To the reaction mixture was added ice-water, and the mixture was extracted with AcOEt. The extract was washed with water and brine, and dried over MgSO 4 . The solvent was removed under reduced pressure and the residue was chromatographed on silica-gel with n-hexane-AcOEt (3 : 1). The eluate was concentrated under reduced pressure to give 7 (18.4 g, 87%) as a yellow oil. was stirred at 70°C for 3.5 h. To the reaction mixture was added ice-water and the resulting mixture was extracted with AcOEt. The extract was washed with water and brine, and dried over MgSO 4 . The solvent was removed under reduced pressure and the residue was chromatographed on silica-gel with n-hexane-AcOEt (1 : 1). The eluate was concentrated under reduced pressure to give 10 (1.1 g, 76%) as a colorless syrup. 1 
N-Methyl-N-phenyl-2-[2-[N-(2-aminoacetyl)-N-(3-methylbutyl)-amino]phenoxy]acetamide (11)
To a solution of 10 (1.0 g, 2.1 mmol) in CH 2 Cl 2 (20 ml) was added TFA (10 ml) with ice cooling, and the mixture was stirred at the same temperature for 1 h. The reaction mixture was concentrated under reduced pressure and the residue was dissolved in CHCl 3 . The organic solution was washed with saturated aqueous NaHCO 3 , water and brine, and dried over MgSO 4 . The solvent was removed under reduced pressure to give 11 (0.8 g, 99%) as a yellow syrup. 
Methyl 2-[3-[3-[N-[2-(N-Methyl-N-phenylcarbamoylmethoxy)phenyl]-N-(3-methylbutyl)carbamoylmethyl]ureido]phenyl]acetate (13)
To a solution of 11 (0.7 g, 1.8 mmol) in THF (20 ml) was added CDI (0.37 g, 2.2 mmol) and the mixture was stirred at room temperature for 10 min. The reaction mixture was concentrated under reduced pressure and the residue was dissolved in toluene (50 ml). After adding 12 (0.7 g, 3.6 mmol) to this solution, the resulting mixture was stirred under reflux for 1 h. The reaction 
2-[3-[3-[N-[2-(N-Methyl-N-phenylcarbamoylmethoxy)phenyl]-N-(3-methylbutyl)carbamoylmethyl]ureido]phenyl]acetic Acid (14)
To a solution of 13 (0.3 g, 0.52 mmol) in THF (6 ml) was added 0.1 N NaOH (6 ml) and the mixture was stirred at room temperature for 5 h. The reaction mixture was acidified with 1 N HCl and the resulting mixture was extracted with CHCl 3 . The extract was washed with brine, and dried over MgSO 4 . The solvent was removed under reduced pressure and the product was recrystallized from CH 2 Cl 2 -AcOEt-diethyl ether. The powder was collected by filtration to give 14 (0.26 g, 89%) as a white powder, mp 147-149°C. 1 8 Hz) .
N-Methyl-N-phenyl-2-(2-aminophenoxy)acetamide (17) 16 (20 g, 69.9 mmol) was hydrogenated in a mixture of MeOH (250 ml) and AcOEt (250 ml) over 5% Pd-C (4 g) at atmospheric pressure for 2.5 h. The catalyst was filtered off and the filtrate was concentrated under reduced pressure. The residue was dissolved in CHCl 3 and the solution was dried over MgSO 4 
N-Methyl-N-phenyl-2-[2-(N-benzylamino)phenoxy]acetamide (18a)
A mixture of 17 (2.6 g, 10 mmol), benzyl bromide (1.7 g, 10 mmol) and K 2 CO 3 (2.1 g, 15 mmol) in DMF (50 ml) was stirred at 70°C for 2 d. To the reaction mixture was added ice-water and the resulting mixture was extracted with AcOEt. The extract was washed with water and brine, and dried over MgSO 4 . The solvent was removed under reduced pressure and the residue was chromatographed on silica-gel with n-hexane-AcOEt (2 : 1). The eluate was concentrated under reduced pressure to give 18a (2.0 g, 58%) as a yellow oil. Compounds 18b-l were obtained by following an analogous procedure to that described for the preparation of 18a. Spectroscopic data for these compounds are as follows: (3H, m) . 
N-Methyl-N-phenyl-2-[2-[N-(n-butyl)amino]phenoxy]acetamide

N-Methyl-N-phenyl-2-[2-[N-benzyl-N-[2-(N-phthaloylamino)acetyl]-amino]phenoxy]acetamide (19a)
Thionyl chloride (0.73 ml, 10 mmol) was added to 2-(N-phthaloylamino)acetic acid (1.6 g, 8.0 mmol) containing a catalytic amount of DMF with ice cooling, and the mixture was stirred under reflux for 0.5 h. The excess thionyl chloride was distilled off and the residue was dissolved in CH 2 Cl 2 (30 ml). This solution was added to a solution of 18a (1.9 g, 5.5 mmol) and pyridine (0.64 ml, 8.0 mmol) in CH 2 Cl 2 (50 ml) with ice cooling, and the resulting mixture was stirred at room temperature for 1 h. The reaction mixture was washed with 1 N HCl, water, saturated aqueous NaHCO 3 and brine, and dried over MgSO 4 . The solvent was removed under reduced pressure and the product was washed with n-hexaneAcOEt to give 19a (2.1 g, 72%) as an off-white solid, mp 162-164°C. 1 Compounds 19b-l were obtained by following an analogous procedure to that described for the preparation of 19a. Spectroscopic data for these compounds, except for 19d and 19e, are as follows. Compounds 19d and 19e were used for the subsequent reaction without purification. 2H, m) . 2H, m) . 2H, m) . 2H, m) . (6H, t, Jϭ6.8 Hz), 1.08-1.26 (7H, m), 1.47-1.48 (2H, m), 3.31 (3H, s) 2H, m) .
N-Methyl-N-phenyl-2-[2-[N-(2-phenylethyl)-N-[2-(N-phthaloylamino)-
N-Methyl-N-phenyl-2-[2-[N-cylcohexylmethyl-N-[2-(N-phthaloylamino)-
N-Methyl-N-phenyl-2-[2-[N-(n-butyl)-N-[2-(N-phthaloylamino)-
N-Methyl-N-phenyl-2-[2-[N-(2-methylpropyl)-N-[2-(N-phthaloylamino)-
N-Methyl-N-phenyl-2-[2-[N-(3-ethylpentyl)-N-[2-(N-phthaloylamino)-
N-Methyl-N-phenyl-2-[2-[N-(4-methyl-3-pentenyl)-N-[2-(N-phthaloy-
N-Methyl-N-phenyl-2-[2-[N-(2-aminoacetyl)-N-benzylamino]phenoxy]-acetamide (20a)
To a solution of 19a (2.0 g, 3.8 mmol) in a mixture of CHCl 3 (20 ml) and EtOH (80 ml) was added hydrazine monohydrate (0.55 ml, 11.4 mmol), and the mixture was stirred overnight at room temperature. The reaction mixture was concentrated under reduced pressure and the residue was suspended in CHCl 3 . The suspension was filtered and the filtrate was concentrated under reduced pressure. The residue was resuspended in CHCl 3 and the suspension was filtered. The filtrate was concentrated under reduced pressure to give crude 20a (1.8 g) as a white amorphous powder. Compound 20a was used for the subsequent reaction without purification. (11H, m) .
Compounds 20b-l were obtained by following an analogous procedure to that described for the preparation of 20a and used for the subsequent reaction without purification. Spectroscopic data for these compounds are as follows: (6H, m) . (6H, m) . (6H, m) . 30 (3H, s), 3.31-3.35 (1H, m), 3.89-3.92 (1H, m) 51 (6H, m) . (6H, m) . 24 (7H, m), 1.44-1.46 (2H, m), 1.91 (2H, br s), 3.04 (1H, d, Jϭ17.1 Hz),  3.16 (1H, d, Jϭ17.1 Hz), 3.26-3.33 (1H, m), 3.30 (3H, s), 3.89-3.94 (1H,  m), 4.44 (2H, s), 6.70 (1H, d, Jϭ8.3 51 (6H, m) .
N-Methyl-N-phenyl-2-[2-[N-(2-aminoacetyl)-N-(2-cyclohexylethyl)-
N-Methyl-N-phenyl-2-[2-[N-(2-aminoacetyl)-N-(3-cyclohexylpropyl)-
N-Methyl-N-phenyl-2-[2-[N-(2-aminoacetyl)-N-(n-butyl)amino]phe-
N-Methyl-N-phenyl-2-[2-[N-(2-aminoacetyl)-N-(2-methylpropyl)amino]-
N-Methyl-N-phenyl-2-[2-[N-(2-aminoacetyl)-N-(4-methyl-3-pentenyl)-
7.8 Hz), 6.99 (1H, d, Jϭ8.8 Hz), 7.07-7.16, 7.25-7.(Ϯ)-N-Methyl-N-phenyl-2-[2-[N-(2-aminoacetyl)-N-(3-methylhexyl)- amino
N-Methyl-N-phenyl-2-[2-[N-(2-aminoacetyl)-N-(4-ethylhexyl)amino]phe-
Compounds 21a-l were obtained by following an analogous procedure to that described for the preparation of 13. Spectroscopic data for these compounds are as follows: Compounds 22a-m were obtained by following an analogous procedure to that described for the preparation of 14; the yields, melting points and elemental analysis data are given in 98 (1H, m), 4.45 (2H, s), 6.52 (1H, s) . N-(2-Benzyloxyphenyl)cyclopropylcarboxamide (24a) To a solution of 23 (4.0 g, 20 mmol) and cyclopropylcarboxylic acid (1.7 g, 20 mmol) in CH 2 Cl 2 (50 ml) were added EDC · HCl (4.6 g, 24 mmol) and DMAP (2.9 g, 24 mmol), and the mixture was stirred overnight at room temperature. The reaction mixture was concentrated under reduced pressure and the residue was partitioned between AcOEt and 1 N HCl. The layers were separated and the organic layer was washed with water, saturated aqueous NaHCO 3 and brine, and dried over MgSO 4 . The solvent was removed under reduced pressure and the product was washed with n-hexane to give 24a (4.7 g, 88%) as a white solid, mp 77-79°C. 1 (1H, br s) .
Compounds 24b-f were obtained by following an analogous procedure to that described for the preparation of 24a. Spectroscopic data for these compounds are as follows:
N-(2-Benzyloxyphenyl)cyclobutylcarboxamide (24b): 68%. 24b was prepared by replacing cyclopropylcarboxylic acid with cyclobutylcarboxylic acid. 1 3 Hz) .
N-(2-Benzyloxyphenyl)-2,2-dimethylpropanamide (24g) To a solution of 23 (4.0 g, 20 mmol) and pyridine (1.8 ml, 22 mmol) in CH 2 Cl 2 (100 ml) was added a solution of 2,2-dimethylpropanoyl chloride (2.7 ml, 22 mmol) in CH 2 Cl 2 (30 ml) with ice cooling, and the mixture was stirred at room temperature for 1.5 h. The reaction mixture was washed with 1 N HCl, water, saturated aqueous NaHCO 3 and brine, and dried over MgSO 4 . The solvent was removed under reduced pressure to give 24g (5.4 g, 95%) as a dark brown oil. 1 8 Hz) .
N-Cyclopropylmethyl-2-benzyloxyaniline (25a) To a solution of 24a (4.0 g, 15 mmol) in THF (50 ml) was added BH 3 -THF complex (1.0 M in THF, 45 ml, 45 mmol) with ice cooling under N 2 , and the mixture was stirred at room temperature for 3 d. After adding ice-water and K 2 CO 3 to the reaction mixture, the resulting mixture was extracted with AcOEt. The extract was washed with brine, and dried over MgSO 4 . The solvent was removed under reduced pressure and the residue was chromatographed on silica-gel with n-hexane-AcOEt (5 : 1). The eluate was concentrated under reduced pressure to give 25a (2.9 g, 76%) as a colorless oil. Compounds 25b-h were obtained by following an analogous procedure to that described for the preparation of 25a. Spectroscopic data for these compounds are as follows:
N-Cyclobutylmethyl-2-benzyloxyaniline (25b): Quant. 
